Raphael Pharmaceutical (RAPH) Cash from Operations (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Cash from Operations of 46000.0 for Q4 2025, up 174.19% on a YoY basis from 16776.47 in Q4 2024, and up 370.59% sequentially from 17000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Cash from Operations (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Cash from Operations data on file, last reported at 46000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 174.19% year-over-year to 46000.0; the trailing twelve-month figure through Dec 2025 stood at 210000.0 (up 60.53% YoY), and the FY2025 full-year result was 210000.0, up 60.53% from the prior year.
- Cash from Operations grew to 46000.0 in Q4 2025, from 17000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 46000.0 in Q4 2025 to a low of 704000.0 in Q4 2021.
- A 5-year average of 206150.0 and a median of 190500.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 386.59% in 2023 and soared 174.19% in 2025, its largest moves.
- Tracing RAPH's Cash from Operations over 5 years: stood at 704000.0 in 2021, then jumped by 60.65% to 277000.0 in 2022, then soared by 68.23% to 88000.0 in 2023, then climbed by 29.55% to 62000.0 in 2024, then jumped by 174.19% to 46000.0 in 2025.
- Business Quant data shows RAPH's Cash from Operations at 46000.0 in Q4 2025, 17000.0 in Q3 2025, and 30000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Mar 31, 2024 | -172,000.00 |
| Mar 31, 2024 | -172,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Sep 30, 2023 | -501,000.00 |
| Sep 30, 2023 | -501,000.00 |